Reaction: Ruxolitinib to 1 product
- Reaction
- Reaction type
- Not Available
- Direction
- Major circulating metabolite?
- No
- Spontaneous?
- No
- Activity
- active
- References
- Shilling AD, Nedza FM, Emm T, Diamond S, McKeever E, Punwani N, Williams W, Arvanitis A, Galya LG, Li M, Shepard S, Rodgers J, Yue TY, Yeleswaram S: Metabolism, excretion, and pharmacokinetics of [14C]INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans. Drug Metab Dispos. 2010 Nov;38(11):2023-31. doi: 10.1124/dmd.110.033787. Epub 2010 Aug 10. [Article]
- Shi JG, Chen X, Emm T, Scherle PA, McGee RF, Lo Y, Landman RR, McKeever EG Jr, Punwani NG, Williams WV, Yeleswaram S: The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers. J Clin Pharmacol. 2012 Jun;52(6):809-18. doi: 10.1177/0091270011405663. Epub 2011 May 20. [Article]
- FDA Approved Drug Products: JAKAFI (ruxolitinib) tablets, for oral use [Link]
- Comments
- This metabolite is formed from a series of undetermined metabolic reactions.
- Enzymes
Enzyme Km Vmax Role Cytochrome P450 3A4 Not Available Not Available implied Cytochrome P450 2C9 Not Available Not Available implied